bristol myers squibb holiday schedule 2021

Gregorian year (common era) Hebrew year. 2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. Your future colleagues at Bristol Myers Squibb are impacting lives every day. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Leixlip, Kildare. 0000042527 00000 n Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. They merged in 1989, creating a powerhouse pharmaceutical company that was the second-largest in the world at the time. There is a pregnancy exposure registry that monitors the outcomes of females who take REVLIMID during pregnancy, or if their male partner takes REVLIMID and they are exposed during pregnancy. LICENSE AGREEMENT. Mily spoke to S&P Global Market Intelligence ahead of the 2021 J.P. Morgan Healthcare Conference beginning Jan. 11 about the company's plans for future M&A and partnerships. In addition, the compounds described in this communication are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Security personnel receive training to ensure compliance with legal requirements and respect for human rights. Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program Research and development expenses decreased 30% to $2.6 billion in the quarter. When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. (, In December, the company announced that its Board of Directors approved an increase in the quarterly dividend and authorized an additional $15 billion, multi-year share repurchase program. July 28 (Reuters) - Bristol Myers Squibb Co (BMY.N) reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after. 0000042754 00000 n Bristol-Myers Squibb has a 1 year low of $54.07 and a 1 year high of $67.16. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. We are committed to following all laws regarding child labor, forced labor and freedom of association. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. (PDF), UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. 0000003660 00000 n Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. Working among other smart, creative and talented colleagues, youll find support and uncommon opportunities to learn, grow and lead. This was driven by its aforementioned revenue growth, a 330-basis-point. Privacy Protection Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy. trailer endobj Our financial strength, dedicated workforce and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation and position the company for sustained growth., $ amounts in millions, except per share amounts. Minor Fasts . View this presentation. Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. <>z{^)P"PPq@ 6/ Many of these vary by location, such as: If you're interested in advancing your career with an innovative team, join our Talent Community to keep in touch about the latest news and opportunities that match your interests. Past events. %%EOF In November, the company announced that the Phase 3 CheckMate -816 trial met the co-primary endpoint of improved event-free survival (EFS) in patients with resectable Stage IB to IIIA non-small cell lung cancer. 0000002184 00000 n 33 days holiday (inc. bank holidays) - prorated - with the option to buy/sell 5 additional days ; Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year? 0000001987 00000 n Our people Our global workforce is made up of over 26,000 passionate people who, in 2021, helped Pandora record the highest earnings to date, led by a refreshed long-term growth strategy. Top 40%. 0000030221 00000 n The effective tax benefit rate was 27.7% in the quarter. No additional data or studies have been requested. International revenues increased 4% to $4.5 billion in the quarter. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Bristol Myers Squibb expects to finance the acquisition with cash on hand. 0000004898 00000 n For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . Normal for industry. Our work is challenging and you shouldn't have to go it alone. 0000042941 00000 n The stock was sold at an average price of $64.21, for a total transaction of $200,270.99. Tuition reimbursement is available to eligible employees who, through their own initiation and desire for development, participate in accredited educational programs that their manager deems will be mutually beneficial to BMS and the employee. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. The company was founded in 1887 and is based in New York, New York. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. In November, the company announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Wednesday, April 28th. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset, said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. . Compliance with data privacy laws on a global basis is an essential business practice for Bristol Myers Squibb. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. 813 0 obj These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibbs business nor reflect Bristol Myers Squibbs underlying business performance. hA 04Fq\GczC. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS, *In excess of +100%. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Your response will be removed from the review this cannot be undone. 11:00 am EST. Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Choosing Your Medical Plan. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. U.S. revenues increased 11% to $7.5 billion in the quarter. Usually give off For the year end holidays too! Bristol-Myers Squibb's report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared TipRanks Team May 19, 2021. 0000006923 00000 n Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real Time Price. Both GAAP and non-GAAP guidance assume current exchange rates. Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History (Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE: BMY) Co and Sanofi (NASDAQ: SNY) SA Following the sale, the senior vice president now directly owns 16,243 shares in the company, valued at $1,042,963.03. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. I am ready to take up a new challenge and I would like to take this opportunity to put the knowledge and skills acquired during my career at the service of my new employer and future colleagues. ** Included as part of the new product portfolio Bristol-Myers Squibb had a positive return on equity of 33.76% and a negative net margin of 14.53%. The benefit choices you make go into effect each January 1 (or on your date of eligibility, if later), and stay in effect through December 31, as long as you remain eligible for benefits. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Currency in USD Follow 2W 10W 9M 70.18 -1.22 (-1.71%) At close: 04:00PM EST 70.40 +0.22 (+0.31%) After hours: 07:43PM EST Time. endstream Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Rosh Chodesh. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. Bristol Myers Squibb posted third quarter revenues of $11.2 billion, a decrease of 3%, driven by recent LOE products (primarily Revlimid) and foreign exchange impacts, partially offset by in-line products (primarily Eliquis and Opdivo) and our new product portfolio . Our employees are expected to adhere to the highest ethical standards in the conduct of our business. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. The company also plans to continue to explore the potential of Turning Point Therapeutics promising pipeline of novel compounds. Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95. Add to Google Calendar. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. After the war and into the 1960s, both Squibb and Bristol-Myers expanded their production and research of antibiotics. We do this in a few ways: We are a culture of savers who recognize the value of saving early and often and seize the opportunities to do so. Gross margin increased from 73.7% to 80.3% in the quarter primarily due to an impairment charge related to marketed product rights in the same period a year ago and lower unwinding of inventory purchase price accounting adjustments. No forward-looking statement can be guaranteed. The company continues to maintain a consistent, balanced approach to capital allocation focused on prioritizing investment for growth through business development along with reducing debt, commitment to dividend growth and share repurchase. xref , bristol myers squibb holiday calendar 2021 2021, bristol myers squibb holiday calendar 2021, Cigna Behavioral Health Provider Phone Number, A Person Will Become Responsible If He/she Is Brainly, Classes Offered At Gateway Community College. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. ***Included as part of the key loss of exclusivity (LOE) brands, *In excess of +100%. Home; Our Services; About us; Blog; Contact The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). The Office of Corporate Conduct is a resource for any employee to confidentially and anonymously report their concerns or raise questions. It offers chemically-synthesized drugs or. (( g Bristol ups aid. Key 2022 GAAP and non-GAAP line-item guidance assumptions are: The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. Image Source: Zacks Investment Research. In addition to day to day coaching and mentoring, members of Our mission to enhance the lives of patients requires an investment in a strong learning culture. Best place for vacation and time off, BMS incentivize family time. Media: media@bms.com 3 floating holidays. 0000011978 00000 n Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow." Senior Research Investigator salaries ($93k), Research Investigator II salaries ($108k), Associate Research Scientist I salaries ($70k), Senior Research Investigator II salaries ($132k), Associate Research Scientist II salaries ($77k). A REMS program was included in the initial application for mavacamten. Add to iCalendar. Monthly calendar; Candle-lighting times only . The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. I had the opportunity to share insights on our Bristol Myers Squibb . All of our employees must comply with the highest standards of data privacy protection consistent with the laws of the jurisdiction in which they operate. 3 floating holidays. Selling, General & Admin. We regularly promote awareness of this resource to employees. Learn more about the cookies we use on our General Privacy Notice page. We foster an energizing work experience, that through your choices, education and access, sustains our environment of well-being, individual accountability, productivity and safety. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer will answer questions about the company at 5 p.m. Bristol-Myers Squibb's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B. Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. Investors. Learn about 2023 benefits. We have the responsibility to protect and respect personal information. There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. schedule conferences . 0000003506 00000 n The tender offer described in this communication has not yet commenced. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. 0000002307 00000 n The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. We believe people learn the most through on-the-job experiences. Year. Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and also available on the companys website at www.bms.com. <<6D48DD0CF1B2B2110A0080F8A4DAFC7F>]/Prev 512677/XRefStm 1987>> We are committed to following all laws regarding child labor, forced labor and freedom of association. <> All comparisons are made versus the same period in 2020 unless otherwise stated. "The first of the new aircraft will enter service in late-2023, with the bulk to . INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Materials related to the call will be available at the same website prior to the conference call. Bristol-Myers Squibb bulls will hope to hear the company announce they've not only beaten. Top 50%. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations.

Allied Universal Transfer Policy, What Happened To Ben Aronoff Family, Lucali Happy Hour Miami, Bbq Smoker Mods Oklahoma Joe, Articles B